GSK: 2-drug HIV treatment as effective as 3-drug regimen
(CercleFinance.com) - A study showed that GlaxoSmithKline's two-drug regimen to treat HIV was as effective as the three-drug regimen, the British drugmaker said on Wednesday.
ViiV Healthcare, the HIV unit of GSK, said a phase III study showed patients were able to maintain similar rates of viral suppression after switching to its two-drug regimen of dolutegravir plus lamivudine.
The study hence met its primary endpoint for non-inferiority.
The single-pill of dolutegravir plus lamivudine was authorised in the United States earlier this year for the treatment of HIV-1 infection in adults with no antiretroviral treatment history.
It was also authorised in Europe this month.
Copyright (c) 2019 CercleFinance.com. All rights reserved.
ViiV Healthcare, the HIV unit of GSK, said a phase III study showed patients were able to maintain similar rates of viral suppression after switching to its two-drug regimen of dolutegravir plus lamivudine.
The study hence met its primary endpoint for non-inferiority.
The single-pill of dolutegravir plus lamivudine was authorised in the United States earlier this year for the treatment of HIV-1 infection in adults with no antiretroviral treatment history.
It was also authorised in Europe this month.
Copyright (c) 2019 CercleFinance.com. All rights reserved.